Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2026-03-18 00:00:00 ET · period of report 2026-03-16 · accession 0001231919-26-000262 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-03-18 | 2026-03-16 | ABOS | Shah Rajeev M. | Dir, 10% | A - Grant | $3.30 | +6.06M | 19.10M | +46% | +$20.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-16 | A | A | 6,060,606 | $3.30 | 19,103,785 | I See footnotes | — | — | (F1) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. |